Literature DB >> 24419518

Deferasirox improves hematopoiesis after allogeneic hematopoietic SCT.

G Visani1, B Guiducci1, C Giardini1, F Loscocco1, T Ricciardi1, A Isidori1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24419518     DOI： 10.1038/bmt.2013.213

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

1.  Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging.

Authors:  Emanuela Messa; Sonia Carturan; Chiara Maffè; Marisa Pautasso; Enrico Bracco; Antonella Roetto; Francesca Messa; Francesca Arruga; Ilaria Defilippi; Valentina Rosso; Chiara Zanone; Antonia Rotolo; Elisabetta Greco; Rosa M Pellegrino; Daniele Alberti; Giuseppe Saglio; Daniela Cilloni
Journal:  Haematologica       Date:  2010-06-09       Impact factor: 9.941

2.  Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes.

Authors:  Hussam Ghoti; Eitan Fibach; Drorit Merkel; Galit Perez-Avraham; Sigal Grisariu; Eliezer A Rachmilewitz
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

3.  Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.

Authors:  Sara Gardenghi; Pedro Ramos; Maria Franca Marongiu; Luca Melchiori; Laura Breda; Ella Guy; Kristen Muirhead; Niva Rao; Cindy N Roy; Nancy C Andrews; Elizabeta Nemeth; Antonia Follenzi; Xiuli An; Narla Mohandas; Yelena Ginzburg; Eliezer A Rachmilewitz; Patricia J Giardina; Robert W Grady; Stefano Rivella
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

4.  Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with β-thalassemia major.

Authors:  Gian Luca Forni; Marina Podestà; Marco Musso; Giovanna Piaggio; Khaled M Musallam; Manuela Balocco; Sarah Pozzi; Alessandra Rosa; Francesco Frassoni
Journal:  Haematologica       Date:  2012-12-14       Impact factor: 9.941

5.  Does iron overload really matter in stem cell transplantation?

Authors:  Philippe Armand; Marie-Michele Sainvil; Haesook T Kim; Joanna Rhodes; Corey Cutler; Vincent T Ho; John Koreth; Edwin P Alyea; Ellis J Neufeld; Raymond Y Kwong; Robert J Soiffer; Joseph H Antin
Journal:  Am J Hematol       Date:  2012-04-04       Impact factor: 10.047

6.  The effect of iron overload and chelation on erythroid differentiation.

Authors:  Kazuki Taoka; Keiki Kumano; Fumihiko Nakamura; Masataka Hosoi; Susumu Goyama; Yoichi Imai; Akira Hangaishi; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2011-12-23       Impact factor: 2.490

Review 7.  Iron overload and allogeneic hematopoietic stem-cell transplantation.

Authors:  Junya Kanda; Hiroshi Kawabata; Nelson J Chao
Journal:  Expert Rev Hematol       Date:  2011-02       Impact factor: 2.929

8.  Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.

Authors:  E Messa; D Cilloni; F Messa; F Arruga; A Roetto; G Saglio
Journal:  Acta Haematol       Date:  2008-10-01       Impact factor: 2.195

9.  Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content.

Authors:  Bryan J Trottier; Linda J Burns; Todd E DeFor; Sarah Cooley; Navneet S Majhail
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

10.  Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation.

Authors:  Sara C Meyer; Alix O'Meara; Andreas S Buser; André Tichelli; Jakob R Passweg; Martin Stern
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-23       Impact factor: 5.742
  10 in total
  7 in total

1.  Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.

Authors:  Carlos Vallejo; Montserrat Batlle; Lourdes Vázquez; Carlos Solano; Antonia Sampol; Rafael Duarte; Dolores Hernández; Javier López; Montserrat Rovira; Santiago Jiménez; David Valcárcel; Vicente Belloch; Mónica Jiménez; Isidro Jarque
Journal:  Haematologica       Date:  2014-07-04       Impact factor: 9.941

Review 2.  Current Review of Iron Overload and Related Complications in Hematopoietic Stem Cell Transplantation.

Authors:  Erden Atilla; Selami K Toprak; Taner Demirer
Journal:  Turk J Haematol       Date:  2016-12-12       Impact factor: 1.831

3.  Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells.

Authors:  Tiziana Tataranni; Carmela Mazzoccoli; Francesca Agriesti; Luciana De Luca; Ilaria Laurenzana; Vittorio Simeon; Vitalba Ruggieri; Consiglia Pacelli; Gerardo Della Sala; Pellegrino Musto; Nazzareno Capitanio; Claudia Piccoli
Journal:  Stem Cell Res Ther       Date:  2019-06-13       Impact factor: 6.832

Review 4.  The Clinical Significance of Iron Overload and Iron Metabolism in Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Authors:  Sarah Weber; Anastasia Parmon; Nina Kurrle; Frank Schnütgen; Hubert Serve
Journal:  Front Immunol       Date:  2021-02-19       Impact factor: 7.561

5.  [Research progress of characteristics and mechanisms of iron overload affecting bone marrow hematopoiesis].

Authors:  L Huang; R Fu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-08-14

6.  Rescue treatment with eltrombopag in refractory cytopenias after allogeneic stem cell transplantation.

Authors:  Semra Aydin; Chiara Dellacasa; Sara Manetta; Luisa Giaccone; Laura Godio; Giorgia Iovino; Benedetto Bruno; Alessandro Busca
Journal:  Ther Adv Hematol       Date:  2020-10-20

Review 7.  Advances in the understanding of poor graft function following allogeneic hematopoietic stem-cell transplantation.

Authors:  Juan Chen; Hongtao Wang; Jiaxi Zhou; Sizhou Feng
Journal:  Ther Adv Hematol       Date:  2020-08-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.